荣先奎

This profile gathers the share dealings of 荣先奎 in 派林生物, where the filings describe the role as senior executive. In total, 3 filings cover trades dated from 2 January 2025 to 25 April 2025.

Every open-market trade on record is a purchase: 3 purchases worth €55k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price.

Half of the purchases are above €14k and half below. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 3 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +1.1%. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 25 April 2025, reports an open-market purchase of €13k in 派林生物. Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. Until a filing is published, the market cannot know about the trade. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.